Stocks · News reference
Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer,
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Propanc Biopharma, Inc. has approved a 1-for-10 reverse stock split of its common stock, effective as of the market open on October 26, 2026, to maintain compliance with Nasdaq listing standards.